Global Pricing Innovations (GPI)’s Post

Over the last few months, we’ve seen countries change their stance on net price transparency 👀 In Spain, we saw new laws requiring the release of net prices whilst in Germany there was talk of making prices more confidential 🤔 Given these changes, we wanted to gather your thoughts on who you thought would be the most impacted stakeholders from increased net price transparency. So, over the last week we posted a poll, which generated a lot of traction! Specifically: 👉 28% of voters believed net price transparency would most impact patients in low- and middle-income countries (LMICs). 👉 6% of voters believed net price transparency would most impact patients in high-income countries (HICs). 👉 56% of voters believed net price transparency would most impact manufacturers. 👉 11% of voters believed net price transparency would most impact payers.   In truth, net price transparency has the potential to impact each listed stakeholder in different ways. It could negatively impact the access of vital treatments to patients in LMICs. It could also lead to further downward pressures on price that could influence manufacturers’ R&D capital required to develop life changing innovative treatments. In our 2024 World EPA poster, we explored the potential risks and benefits, and the winners and losers from opening Pandora’s Box that is net price transparency. Click the link to download our poster: https://lnkd.in/dyzV75cW

Form

Form

share.hsforms.com

To view or add a comment, sign in

Explore topics